0
December 12, 2012, Vol 308, No. 22 >

Full Content is available to subscribers

Subscribe/Learn More
Preliminary Communication | December 12, 2012 ONLINE FIRST

Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy:  The POSEIDON Randomized Trial

Joshua M. Hare, MD; Joel E. Fishman, MD, PhD; Gary Gerstenblith, MD; Darcy L. DiFede Velazquez, RN, BSN; Juan P. Zambrano, MD; Viky Y. Suncion, MD; Melissa Tracy, MD; Eduard Ghersin, MD; Peter V. Johnston, MD; Jeffrey A. Brinker, MD; Elayne Breton, BSN, RN; Janice Davis-Sproul, MAS; Ivonne H. Schulman, MD; John Byrnes, MD; Adam M. Mendizabal, MS; Maureen H. Lowery, MD; Didier Rouy, MD, PhD; Peter Altman, PhD; Cheryl Wong Po Foo, PhD; Phillip Ruiz, MD; Alexandra Amador, BSMT; Jose Da Silva, PhD; Ian K. McNiece, PhD; Alan W. Heldman, MD
JAMA. 2012;308(22):2369-2379. doi:10.1001/jama.2012.25321.
Text Size: A A A
Published online
Article
Figures
Tables
References

Context  Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible; however, their safety and efficacy have not been compared.

Objective  To test whether allogeneic MSCs are as safe and effective as autologous MSCs in patients with left ventricular (LV) dysfunction due to ICM.

Design, Setting, and Patients  A phase 1/2 randomized comparison (POSEIDON study) in a US tertiary-care referral hospital of allogeneic and autologous MSCs in 30 patients with LV dysfunction due to ICM between April 2, 2010, and September 14, 2011, with 13-month follow-up.

Intervention  Twenty million, 100 million, or 200 million cells (5 patients in each cell type per dose level) were delivered by transendocardial stem cell injection into 10 LV sites.

Main Outcome Measures  Thirty-day postcatheterization incidence of predefined treatment-emergent serious adverse events (SAEs). Efficacy assessments included 6-minute walk test, exercise peak VO2, Minnesota Living with Heart Failure Questionnaire (MLHFQ), New York Heart Association class, LV volumes, ejection fraction (EF), early enhancement defect (EED; infarct size), and sphericity index.

Results  Within 30 days, 1 patient in each group (treatment-emergent SAE rate, 6.7%) was hospitalized for heart failure, less than the prespecified stopping event rate of 25%. The 1-year incidence of SAEs was 33.3% (n = 5) in the allogeneic group and 53.3% (n = 8) in the autologous group (P = .46). At 1 year, there were no ventricular arrhythmia SAEs observed among allogeneic recipients compared with 4 patients (26.7%) in the autologous group (P = .10). Relative to baseline, autologous but not allogeneic MSC therapy was associated with an improvement in the 6-minute walk test and the MLHFQ score, but neither improved exercise VO2 max. Allogeneic and autologous MSCs reduced mean EED by −33.21% (95% CI, −43.61% to −22.81%; P < .001) and sphericity index but did not increase EF. Allogeneic MSCs reduced LV end-diastolic volumes. Low-dose concentration MSCs (20 million cells) produced greatest reductions in LV volumes and increased EF. Allogeneic MSCs did not stimulate significant donor-specific alloimmune reactions.

Conclusions  In this early-stage study of patients with ICM, transendocardial injection of allogeneic and autologous MSCs without a placebo control were both associated with low rates of treatment-emergent SAEs, including immunologic reactions. In aggregate, MSC injection favorably affected patient functional capacity, quality of life, and ventricular remodeling.

Trial Registration  clinicaltrials.gov Identifier: NCT01087996
Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Figure 1. Study Flow Diagram
Grahic Jump Location
+Image not available.
View Large  |  Save Figure  |  Download Slide (.ppt)  |  View in Article Context
Image not available.

MSCs indicates mesenchymal stem cells; LV, left ventricular.

Place holder to copy figure label and caption
Figure 2. Functional Outcomes of the Effect of Allogeneic and Autologous Mesenchymal Stem Cell (MSC) Transendocardial Stem Cell Injection on Patient Functional Capacity and Quality of Life
Grahic Jump Location
+Image not available.
View Large  |  Save Figure  |  Download Slide (.ppt)  |  View in Article Context
Image not available.

A, Autologous but not allogeneic MSC therapy was associated with an improvement in the 6-minute walk test. When considering both groups combined, patients exhibited increased 6-minute walk test distance in both groups (P = .003 for analysis of variance with repeated measures; P = .004 vs baseline for all patients; and P = .21 for cell type × time interaction). B, Patients exhibited no change in peak exercise oxygen consumption per unit time (VO2 max). C, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score improved in the autologous but not the allogeneic group. When considering both groups combined, MLHFQ scores improved (P < .001 for analysis of variance with repeated measures; and P = .54 for cell type × time interaction). D, Change in New York Heart Association classification from 12 months to baseline is shown as the proportion of patients who either improved, did not change, or worsened. Individual patient values for the 6-minute walk test, peak VO2, and total score of the MLHFQ are shown across time as gray lines with the corresponding cell type mean and 95% CIs indicated by bars and shaded across time. Within-group P values are noted as aP <.05 and bP <.01.

Place holder to copy figure label and caption
Figure 3. Computed Tomography (CT) Parameters Change From Baseline
Grahic Jump Location
+Image not available.
View Large  |  Save Figure  |  Download Slide (.ppt)  |  View in Article Context
Image not available.

MSCs indicates mesenchymal stem cells; EED, early enhancement effect. Mean changes from baseline to 13 months are noted by triangles and depict change in cardiac phenotype assessed by cardiac CT scan. Error bars indicate 95% CIs. Individual patient changes from baseline are shown as circles. Shown are changes in cardiac structural and functional parameters from baseline to 13-month follow-up in allogeneic, autologous, and combined patient groups. Within-group P values are noted as aP <.05, bP <.01, and cP <.001.

Place holder to copy figure label and caption
Figure 4. Improvement in Early Enhancement Defect (EED) After Transendocardial Allogeneic Stem Cell Injection
Grahic Jump Location
+Image not available.
View Large  |  Save Figure  |  Download Slide (.ppt)  |  View in Article Context
Image not available.

Upper panel, baseline early-phase short-axis multidetector computed tomography images in a representative patient with chronic myocardial infarction (EED total, 40.34 g). Lower panel, 13 months after transendocardial stem cell injection of allogeneic mesenchymal stem cells (100 million cells). There was a decrease of 34.68% in EED (26.35 g). The reduction of the myocardial defects was accompanied by decrease of end-diastolic volume from 433.68 mL to 365.81 mL, decrease of end-systolic volume from 371.83 mL to 277.38 mL, increase of ejection fraction from 14.26% to 24.17%, and improvement of sphericity index from 0.60 to 0.51. See Interactive of the patient’s 3D multidetector tomography scan reconstructions showing the EED before and after transendocardial stem cell injection.

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Letters

Submit a Letter
April 10, 2013
Use of Stem Cells for Ischemic Cardiomyopathy
Guo-You Zhang, MD; Qing-Feng Li, MD, PhD; Xiao-Bing Fu, MD, PhD
JAMA. 2013;309(14):1458-1459. doi:10.1001/jama.2013.2890.
April 10, 2013
Use of Stem Cells for Ischemic Cardiomyopathy—Reply
Joshua M. Hare, MD; Darcy Difede, RN; Alan W. Heldman, MD
JAMA. 2013;309(14):1458-1459. doi:10.1001/jama.2013.2893.
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
Jobs

More Listings at
JAMACareerCenter.com >

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems